Sunday, June 1, 2025
VISIT ROYALMOK
Agarwood Times
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
No Result
View All Result
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
No Result
View All Result
Agarwood Times
No Result
View All Result

Johnson & Johnson Discontinues Pivotal Depression Drug Trial Due to Lack of Efficacy

March 8, 2025
in Health
Reading Time: 3 mins read
0 0
A A
0
Home Health
Share on FacebookShare on Twitter


A despair drug candidate that’s a key a part of Johnson & Johnson’s neuroscience technique has failed a Part 3 scientific trial, the most recent dose of disappointing information for an rising class of medicines addressing a novel goal hoped to beat limitations of at the moment accessible antidepressants.

J&J is discontinuing the Part 3 check of its drug, aticaprant, in main depressive dysfunction “as a consequence of inadequate efficacy within the goal affected person inhabitants,” the corporate stated after Thursday’s market shut. The pharmaceutical large stated this drug was secure and well-tolerated by sufferers, and no new security indicators have been recognized. No different particulars in regards to the trial outcomes have been disclosed.

The open-label scientific trial’s focused enrollment was 840 adults ages 18 to 74. Individuals obtained aticaprant as soon as day by day as an adjunct to despair medicine they have been already taking. Efficacy objectives for the 54-week examine embrace measuring the proportion of sufferers with suicidal ideas or behaviors in addition to the change in rating over time in line with a scale used to evaluate despair signs.

The trial additionally measured for weight acquire and sexual dysfunction, opposed results which might be widespread with at the moment accessible despair medicines and lead many sufferers to cease taking them. Aticaprant was hoped to keep away from or not less than scale back these unwanted side effects. Higher efficacy and improved security and tolerability can be key benefits over the present slate of antidepressants. Analysts had projected aticaprant would grow to be a blockbuster product.

J&J stated evaluation of the failed examine is underway and extra particulars will likely be introduced at a future medical assembly. However despite the fact that this Part 3 trial is ending, J&J isn’t giving up on aticaprant. Primarily based on the potential of the drug’s mechanism, the corporate stated it’s going to discover future improvement alternatives in different areas of excessive unmet want.

Aticaprant is a small molecule designed to focus on and block kappa opioid receptors, an method supposed to modulate pathways that regulate temper and conduct. It’s the identical goal hit by Neumora Therapeutics’ lead drug candidate, navacaprant. In January, Neumora reported this day by day capsule didn’t beat a placebo on the primary efficacy aim of a Part 3 scientific trial.

Earlier this week, Neumora stated it’s going to finish the failed Part 3 examine, one in all three late-stage assessments for navacaprant. However the firm additionally stated it’s going to apply learnings from the failed check to the 2 different Part 3 research, which have been paused for now. Adjustments embrace optimizing web site choice and enhancing medical monitoring to make sure acceptable sufferers are enrolled. Neumora plans to renew the 2 research later this month; preliminary knowledge are anticipated in 2026. Neumora additionally stopped a Part 2 check of navacaprant in bipolar despair so as to commit its sources to its main depressive dysfunction scientific analysis.

[Paragraph added with analyst comments.] In a be aware despatched to buyers Friday, William Blair analyst Myles Minter acknowledged Neumora’s explanations for the trial failure and the deliberate changes to the 2 different Part 3 assessments. However he added that the back-to-back Part 3 misses for Neumora and J&J towards the kappa opioid receptor diminishes confidence on this goal as a mechanism for treating main depressive dysfunction. The agency has lowered the Neumora examine’s likelihood of success to five% and likewise downgraded the biotech’s shares.

As for J&J, the corporate’s neuroscience portfolio consists of the blockbuster schizophrenia drug Invega and the nasal spray despair drug Spravato. The pharma large is bringing a despair drug prospect into the fold by way of the $14 billion acquisition of Intra-Mobile Therapies introduced in January. Intra-Mobile’s fundamental asset is Caplyta, which has approvals in schizophrenia and bipolar despair. The drug is at the moment beneath FDA evaluate for main depressive dysfunction, a sign that would make the once-daily capsule a blockbuster vendor. J&J expects to finish the Intra-Mobile acquisition later this 12 months.

Picture: Mario Tama, Getty Photos



Source link

Tags: DepressionDiscontinuesDrugdueefficacyJohnsonLackpivotaltrial
Previous Post

AI unlocks genetic keys to better colorectal cancer survival

Next Post

Please participate in the RUC survey of unattended sleep testing codes

Related Posts

Quality of kids’ diets linked with dad’s eating habits as a teen
Health

Quality of kids’ diets linked with dad’s eating habits as a teen

May 31, 2025
Diagnostics.ai launches fully-transparent machine learning platform for real-time PCR diagnostics
Health

Diagnostics.ai launches fully-transparent machine learning platform for real-time PCR diagnostics

May 31, 2025
Astellas Stays Competitive in Hot Gut Cancer Target, Paying 0M to License Evopoint Drug
Health

Astellas Stays Competitive in Hot Gut Cancer Target, Paying $130M to License Evopoint Drug

May 31, 2025
New HHS document details deep NIH cuts as part of Trump budget request
Health

New HHS document details deep NIH cuts as part of Trump budget request

May 31, 2025
Who should be screened for skin cancer?
Health

Who should be screened for skin cancer?

May 30, 2025
Trump Pushes Debunked Theory of ‘Transgender Mice’ as He Thanks Musk for His ‘Service’
Health

Trump Pushes Debunked Theory of ‘Transgender Mice’ as He Thanks Musk for His ‘Service’

May 31, 2025
Next Post
Please participate in the RUC survey of unattended sleep testing codes

Please participate in the RUC survey of unattended sleep testing codes

Interim data on flu vaccines estimate overall moderate protection in Europe, China

Interim data on flu vaccines estimate overall moderate protection in Europe, China

US flu ebbs for third straight week, but impact on healthcare remains

US flu ebbs for third straight week, but impact on healthcare remains

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED

Long-Term Health Impacts of Common Car-Crash Injuries
Health

Long-Term Health Impacts of Common Car-Crash Injuries

by admin
May 28, 2025
0

Automotive collisions are normally framed as single, dramatic occasions - a sudden screech of brakes, a jolt, a visit to...

You’re Not Sick—You’re UnderNourished: How Toxins and Nutrient Deficiencies Converge in Parkinson’s

You’re Not Sick—You’re UnderNourished: How Toxins and Nutrient Deficiencies Converge in Parkinson’s

May 30, 2025
Briefing on the Seventy-Eighth Meeting of CITES Standing Committee | CITES SC78

Briefing on the Seventy-Eighth Meeting of CITES Standing Committee | CITES SC78

May 26, 2025
Walkability Wins: Fourty-Two

Walkability Wins: Fourty-Two

May 31, 2025
The new Covid variant NB.1.8.1 is driving infections in Australia. A virologist explains what you need to know | Lara Herrero for the Conversation

The new Covid variant NB.1.8.1 is driving infections in Australia. A virologist explains what you need to know | Lara Herrero for the Conversation

May 30, 2025
Delicious Protein Coffee Recipe (29g of Protein)

Delicious Protein Coffee Recipe (29g of Protein)

May 29, 2025
Facebook Twitter Instagram Youtube RSS
Agarwood Times

Stay informed with the latest news, articles, and insights on agarwood cultivation, history, sustainability, and more. Explore the timeless allure of agarwood and deepen your understanding of this extraordinary natural resource.

CATEGORIES

  • Agarwood
  • Diet & Fitness
  • Diseases
  • Health
  • Meditation
  • Nutrition
  • Sleep Info
  • Uncategorized
No Result
View All Result

SITEMAP

  • About us
  • Advertise With Us
  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Agarwood
  • Health
  • Diseases
  • Diet & Fitness
  • Nutrition
  • Sleep Info
  • Meditation
  • Shop
VISIT ROYALMOK

Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In